Thrombosis and Hemostasis Biomarkers Market Size, Share, and Industry Analysis, By Product Type (Instruments and Reagents & Consumables), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Disseminated Intravascular Coagulation (DIC), and Others), By End-user (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Regional Forecast, 2025-2032

Thrombosis and hemostasis biomarkers are the laboratory parameters derived from the components of the hemostatic system, such as von Willebrand factor (vWF), fibrinogen, D-dimer, and others. These biomarkers are helpful in the detection of certain diseases or their pathophysiological effects and have various applications in clinical practice.

The benefits of thrombosis and hemostasis biomarkers include the risk estimation and the diagnosis of venous thromboembolism (VTE) and other conditions. Additionally, it helps in the prediction of thrombotic events in patients with lymphoma, response to chemotherapy in patients with pancreatic cancer, and enhanced patient management.

The growth of thrombosis and hemostasis biomarkers is highly attributed to the increased risk of venous thromboembolism (VTE). The risk of venous thromboembolism (VTE) is associated with various clinical conditions such as cardiovascular, cerebrovascular, and malignant disorders. In addition, the risk increases with major or minor injuries and obesity.

• For instance, as per the article published by the American Heart Association, Inc. in November 2023, obese individuals have an increased risk of venous thromboembolism (VTE), and the higher the risk becomes as the weight increases.

Biomarkers such as D-dimer, fibrinogen, and factor VIII are used to predict the risk of venous thromboembolism (VTE) and monitor treatment response. This is expected to significantly boost the adoption of biomarker products, propelling the market growth during the forecast timeframe.

Furthermore, advances in cancer diagnosis and treatment are significantly leading to the growth of thrombosis and hemostasis biomarkers. Cancer patients often exhibit systemic hypercoagulability, which increases the risk of thrombotic complications. Hemostatic biomarkers such as fibrinogen, D-dimer, and thrombin-antithrombin complex are used to monitor cancer activity and predict treatment outcomes. This is anticipated to surge the demand for hemostatic biomarkers, thereby boosting the market growth in the forthcoming years.

The COVID-19 pandemic led to a heightened awareness of the risk of thrombotic and thromboembolic events in patients. As a result, there was a greater need for biomarkers to assess and monitor these risks. This surged the use of hemostasis analyzers and thrombosis reagents, increasing sales during the pandemic. This significantly contributed to the market growth in 2020.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries/Region, 2023
• Key Industry Developments By Key Companies
• New Product Launches, By Key Companies
• Impact of COVID-19 on the Market       
• Overview: Technological Advancements in Thrombosis and Hemostasis Biomarkers Products

Analysis by Product Type

Based on product type, the market is segmented into instruments and reagents & consumables. The reagents & consumables segment is projected to account for a significant share of the global thrombosis and hemostasis biomarkers market during the forecast period. The introduction of high-throughput screening methods, next-generation sequencing, and molecular diagnostics has streamlined the identification and validation of novel thrombosis and hemostasis biomarkers, enhancing the accuracy and sensitivity of biomarker detection. This is increasing the demand for reagents & consumables, which is expected to boost the market growth.

On the other hand, the instruments segment is projected to expand at a noteworthy CAGR during the forecast timeframe. The increasing trend of adopting point-of-care (POC) analyzers in the thrombosis and hemostasis biomarkers market is fueling the growth of analyzers. Advancements in technology, such as the development of mini- and microdevices for the detection of blood clots, are anticipated to fuel the demand for analyzers, driving the market growth.

• For instance, in June 2022, Dr. Arnold Lining Ju developed a microdevice that can detect early signs of blood clots.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to hold a significant share of the thrombosis and hemostasis biomarkers market during the forecast period. The active exploration of the complex mechanisms involved in thrombosis and hemostasis by academic institutions, research organizations, and biotechnology companies in the U.S. is expected to contribute to identifying and validating reliable biomarkers. Moreover, the growing incidence of blood-related disorders and cancer is anticipated to surge the demand for thrombosis and hemostatic biomarkers in the region.

• For instance, according to the Leukemia & Lymphoma Society, an estimated 184,720 individuals in the U.S. are expected to be diagnosed with lymphoma, leukemia, or myeloma in 2023.

Asia Pacific is projected to grow at a significant CAGR during the forecast timeframe. The establishment of specialized hemophilia treatment centers in the region improves access to advanced treatments and contributes to the demand for thrombosis and hemostasis biomarkers. The growing incidence of chronic conditions such as pancreatic cancer, as well as the increasing geriatric population, is contributing to the growing demand for thrombosis and hemostasis biomarkers in the market.

Key Players Covered

The market consists of significant players, such as BIOMÉRIEUX, QuidelOrtho Corporation, Stago Group, F. Hoffmann-La Roche Ltd, BioMedica Diagnostics, Siemens Healthcare Private Limited, Abbott, and HORIBA Medical. The increasing focus of these players on new product launches has been fueling their revenue growth.

Key Industry Developments

• In April 2024, Haemonetics Corporation received FDA 510(k) clearance for its TEG 6s hemostasis analyzer system assay cartridge. This extended the company’s TEG 6s viscoelastic testing capabilities.
• In April 2024, Siemens Healthcare Private Limited and Sysmex Corporation began the distribution of a wide hemostasis testing portfolio to laboratories in the U.S. and Europe.
• In October 2021, Trivitron Healthcare launched a new line of coagulation analyzer products in partnership with Diagon-Vanguard Diagnostics India for the Indian Diagnostics Market.